Core Viewpoint - The current bull market driven by AI raises the question of whether it remains concentrated among a few mega-cap stocks or if broader market participation is emerging [1]. Group 1: Relative Strength Analysis - Relative strength is calculated by dividing the price of one market by another, indicating which market is outperforming [2]. - Various ETFs can be analyzed using relative strength, such as consumer discretionary versus consumer staples and large-cap versus small-cap stocks [3][4]. Group 2: Market Participation - The analysis focuses on the S&P 500 using both market cap weighted and equal weighted calculations to assess participation from larger versus smaller stocks [5]. - A rising relative strength line indicates that larger stocks are dominating performance, while a declining line suggests broader participation from the index [6]. Group 3: Historical Context - Historical data shows a peak concentration during the dot-com boom, followed by a broader market rally until 2010, and a recent trend of increasing concentration again, aligning with the performance of the MAG7 stocks [7][10]. - The past few years have been characterized by the development of AI capabilities, with expectations that the next phase will involve broader economic participation from more companies [8]. Group 4: Future Expectations - The focus for 2026 is on whether more companies within the S&P 500 will contribute to market performance, rather than solely on the performance of mega-cap stocks like Nvidia and Tesla [12]. - Cyclical industries such as industrials, retail, and banks are expected to benefit from growth in the first half of 2026, indicating a potential for broader market participation [13].

Hello and welcome to Asking for a Trend. I'm Josh Lipton and for the next half hour, we are breaking down the trends of today that'll move stocks tomorrow. There's a lot to keep track of, so we're focusing on what you need to know to get ahead of the curve. Here's some of the trends we're going to be diving right into.Earnings season ramp it up, especially with big tech on the horizon. And we've got the scorecard so far, plus a look at whether we could see market gains expand beyond tech. One of those compa ...

Core Insights - Simplicity in trading strategies is emphasized, with a focus on using a few reliable indicators to avoid analysis paralysis [1][7] - Relative strength is highlighted as a powerful indicator, particularly during market downturns, to identify stocks that outperform the market [2][3][7] Company Highlights - **Advanced Micro Devices (AMD)**: Anticipation for the Helios Platform and MI450 release has driven up shares, with analysts projecting a 60.33% growth in EPS by 2026 [4][5] - **Baidu (BIDU)**: Positive developments include the Ernie AI assistant surpassing 200 million monthly active users and the expansion of the Apollo Go robotaxi service, alongside potential spin-off of its AI chip unit, Kunlunxin [8] - **Astera Labs (ALAB)**: The company has shown resilience in a down market, with expectations of strong revenue growth and profitability, regaining its 50-day moving average [8] - **Critical Mineral Stocks**: Companies like United States Antimony (UAMY) have seen significant gains due to geopolitical tensions and tariff disputes, highlighting the importance of onshoring critical mineral production [11] Market Trends - Small-cap stocks have outperformed larger indices, with the Russell 2000 Index up nearly 7% year-to-date, contrasting with a slight decline in the Nasdaq 100 Index ETF [10]

Group 1 - The article highlights the focus on AI data centers and all-renewable electricity as a key target for a member of the Mag 7 [1] - It mentions that ASML Holding, Emcor Group, and ASE Technology are among the stocks listed for their relative strength at new highs [1] - Emcor Group is noted as being in a buy zone, indicating a potential investment opportunity [4] Group 2 - The stock market is experiencing fluctuations, with the Dow Jones dipping after a volatile day, while Advanced Micro Devices shows significant gains [4] - ASML stock is rising due to strong orders and a positive outlook for 2026, suggesting robust demand in the semiconductor sector [4] - The article indicates that the Q3 earnings season is expected to accelerate, which may impact stock performance across various sectors [4]

RT Alan (@0xAlan_)I own zero (0) $USELESS, but its relative strength isn't going unnoticed.Study alts showing early signs of pressure to break out on days where BTC.D is bullish while most alts remain stagnant.Then study what happens to an ecosystem when its leader starts outperforming.Some of us are grossly underexposed to @bonk_fun eco and it shows. ...

#USELESS coin once again displaying incredible relative strength!it's currently outperforming majors like $BTC, $ETH, $SOL and $HYPEit also stands out impressively compared to memecoins like $DOGE, $TRUMP, $SPX, #FARTCOIN and $WIFthis reminds me of how $USELESS consistently outperformed everything during down markets when it had its first parabolic rally from $4.2m to $420m market cap ...

RT Crypto Seth (@seth_fin)USELESS relative strength should be studied. 💥🔥Holding strong while #altcoins are dipping. ...

Market Overview - The S&P 500 has experienced a significant rally, increasing over 60% from its 2023 lows to 2025 highs, driven by Federal Reserve rate cuts, AI enthusiasm, and post-election optimism regarding lower taxes and deregulation [1][31] - Recently, the S&P 500 has pulled back by as much as 10% from its peak due to concerns over tariffs, prompting profit-taking among investors [2][31] 2025 Winners - Despite the market pullback, certain stocks have shown resilience and strong performance, indicating potential leadership in the next market rally. Top performers year-to-date include Sandisk (+52%), CVS Health (+48%), Super Micro Computer (+40%), Phillip Morris (+25%), and Vertex Pharmaceuticals (+24%) [5][6] Key Factors Supporting Bullish Outlook 1. **Easing Monetary Policy**: The Federal Reserve's interest rate cuts, prompted by declining inflation, have made equities more attractive compared to money market funds, which held $6.67 trillion in assets as of November 2024 [11][12] 2. **AI/Quantum Euphoria**: The AI sector has seen substantial gains, with stocks like Innodata (+675%) and Rigetti Computing (+466%) demonstrating significant year-over-year increases, indicating ongoing investment opportunities in this space [14][15] 3. **Potential Tariff Resolution**: If trade war rhetoric diminishes and clarity on future policies emerges, the market could experience a notable rally, supported by corporate tax cuts and deregulation [16][17] Investor Strategy - A disciplined approach is recommended for navigating the current market conditions, including identifying stocks with relative strength during corrections, being open to further pullbacks, and creating a wishlist of potential investments [4][29][30] - Key technical levels for buying dips and selling rips have been identified, with specific price points for the S&P 500 to watch [26][27] Conclusion - The overall market outlook remains positive despite recent volatility, with major themes such as easing monetary policy, the AI boom, and potential tariff resolution continuing to support a bullish case for equities [31][32]

Industry Overview - The Zacks Medical – Biomedical and Genetics industry group ranks in the top 26% out of over 250 industries, indicating strong performance and potential for continued outperformance over the next 3 to 6 months [7] - The industry group has favorable metrics, with a PEG ratio of 1.57 and projected EPS growth of 13.18%, compared to the iShares S&P 500's PEG ratio of 2.12 and projected EPS growth of 6.87% [9] Company Highlights - Gilead Sciences (GILD) is a leading stock in the biomedical sector, known for its innovative medicines for life-threatening illnesses. It has a Zacks Rank of 2 (Buy) and has a trailing four-quarter average earnings surprise of 19.5% [11][12] - GILD reported fourth-quarter earnings of $1.90 per share, exceeding consensus estimates by 13.8%. The stock is trading at 14.5 times forward earnings and has increased over 23% in 2025, reaching a 52-week high [12][13] - Jazz Pharmaceuticals (JAZZ) is another strong performer in the same industry, holding a Zacks Rank of 1 (Strong Buy). The company focuses on neuroscience and oncology and has surpassed earnings estimates in three of the past four quarters [15][16] - JAZZ reported fourth-quarter earnings of $6.60 per share, a 14% surprise over consensus estimates. The stock trades at six times forward earnings, significantly below the industry average, and has advanced more than 11% this year [16][17][18] Investment Strategy - The Zacks Rank methodology helps identify stocks with positive earnings estimate revisions, which can lead to better investment outcomes. Stocks with a Zacks Rank of 3 or better and a positive Earnings ESP have produced positive surprises 70% of the time [20] - JAZZ has a Zacks Rank of 1 and an Earnings ESP of +3.6%, indicating potential for another earnings beat in the upcoming Q1 results [21]